- New approach could be alternative to surgical implantation of radioactive “seeds.”
- Injected radioactive substance was retained in tumors in mice.
- Tumor growth was delayed in all treated animals.
Some patients with solid tumors, including prostate cancer, are treated using a clinical technique called brachytherapy. Brachytherapy involves the surgical implantation of radioactive “seeds” within a patient’s tumor to expose the tumor cells to high levels of radiation while minimizing the negative side effects of radiation on the rest of the body.
“The use of brachytherapy is limited by several factors,” said Wenge Liu, M.D., Ph.D., associate research professor of biomedical engineering at Duke University in Durham, N.C. “The most prominent factor is the need for surgical implantation and removal of the seeds. We set out to develop an alternative approach to brachytherapy that would eliminate the need for surgery.”
Liu and his colleagues generated an injectable substance, called a polymer, attached to a source of radioactivity that spontaneously assembled into a radioactive seed after being injected into a tumor.
In all mice transplanted with either a human head and neck cancer cell line or a human prostate cancer cell line, injection of the radioactive polymers into the growing tumors substantially delayed tumor growth. In more than 67 percent of the animals, the tumors were eradicated by a single injection. Further analysis indicated no signs that cells outside the tumor had been exposed to significant amounts of radiation in any of the animals injected with the radioactive polymers.
“We believe that this approach provides a useful alternative to existing brachytherapy, which requires a complicated surgical procedure to implant the radioactive seeds,” Liu said. “Moreover, these injectable seeds degrade after the radiation is exhausted, so they do not need to be surgically removed.”
About the American Association for Cancer Research
Founded in 1907, the American Association for Cancer Research (AACR) is the world’s first and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer. AACR membership includes more than 34,000 laboratory, translational and clinical researchers; population scientists; other health care professionals; and cancer advocates residing in more than 90 countries. The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, biology, diagnosis and treatment of cancer by annually convening more than 20 conferences and educational workshops, the largest of which is the AACR Annual Meeting with more than 17,000 attendees. In addition, the AACR publishes seven peer-reviewed scientific journals and a magazine for cancer survivors, patients and their caregivers. The AACR funds meritorious research directly as well as in cooperation with numerous cancer organizations. As the scientific partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration and scientific oversight of team science and individual grants in cancer research that have the potential for near-term patient benefit. The AACR actively communicates with legislators and policymakers about the value of cancer research and related biomedical science in saving lives from cancer.
For more information about the AACR, visit www.AACR.org.